Replication of the CANVAS Diabetes Trial in Healthcare Claims
NCT03936010 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152202
Last updated 2023-07-27
Summary
Investigators are building an empirical evidence base for real world data through large-scale replication of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Conditions
Interventions
- DRUG
-
Canagliflozin
Canagliflozin dispensing claim is exposure
- DRUG
-
DPP-4 inhibitor
DPP4 inhibitor dispensing claim is reference
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Shirley Wang, PhD, ScM · Brigham and Womens
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-09-22
- Primary Completion
- 2021-02-18
- Completion
- 2021-02-18
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
NCT03492580 ·Status: COMPLETED
-
The Efficacy and Tolerability of Canagliflozin in Healthy Individual
NCT06301529 ·Status: COMPLETED ·Phase: PHASE4
-
Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes
NCT02964585 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
NCT01106651 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus
NCT01483781 ·Status: COMPLETED ·Phase: PHASE1
-
Replication of the EMPAREG Diabetes Trial in Healthcare Claims
NCT04215536 ·Status: COMPLETED
-
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT01165268 ·Status: COMPLETED ·Phase: PHASE1
-
Mechanisms of Weight Loss With SGLT2 Inhibition
NCT02360774 ·Status: COMPLETED ·Phase: PHASE4
-
STUDY OF PF-06882961 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WITH VARYING DEGREES OF RENAL IMPAIRMENT AND PARTICIPANTS WITHOUT RENAL IMPAIRMENT
NCT04616027 ·Status: COMPLETED ·Phase: PHASE1
-
An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada
NCT02688075 ·Status: COMPLETED
-
Mechanism of SGLT2 Inhibition in the Kidney
NCT06291155 ·Status: RECRUITING ·Phase: PHASE4
-
Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers
NCT01665638 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
NCT01867307 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Empagliflozin on Arterial Wall Characteristics
NCT03639545 ·Status: UNKNOWN ·Phase: PHASE4
-
Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers
NCT02404870 ·Status: COMPLETED ·Phase: PHASE1
-
Renal Impairment in Type 2 Diabetic Subjects
NCT00554450 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes
NCT02413398 ·Status: COMPLETED ·Phase: PHASE3
-
Glycemic Efficacy and Renal Safety Study of Dapagliflozin in Subjects With Type 2 Diabetes Mellitus and Moderate Renal Impairment
NCT00663260 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus
NCT02000700 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents
NCT01939496 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
The Effect of Food on the Administration of Canagliflozin in Healthy Adult Volunteers
NCT01343290 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers
NCT01733108 ·Status: COMPLETED ·Phase: PHASE1
-
A Pharmacokinetic and Pharmacodynamic Study of Once-Daily and Twice-Daily Dosing With Canagliflozin in Healthy Adult Volunteers
NCT01286103 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Empagliflozin (BI 10773) in Patients With Type 2 Diabetes and Renal Impairment
NCT01164501 ·Status: COMPLETED ·Phase: PHASE3